ArticleFrontiers in immunology2026

Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis.

Yu Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.